Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates

  • days left to enroll
  • participants needed
  • sponsor
    Mayo Clinic
Updated on 31 July 2021
ct scan


The Investigators hypothesize that VFA+ DXA is as effective in evaluation of asymptotic vertebral fractures compared to the current gold standard of spine x-ray. In addition, bone turnover markers in transplant patients are unknown. The investigators want to investigate bone turnover markers (Beta CTX and P1NP) as markers of bone health in patients listed for liver transplant.

Condition Osteopenia, Secondary Osteoporosis, Transplant-Related Disorder, Transplant-Related Disorder, Transplant-Related Disorder, Transplant-Related Disorder, metabolic bone disease, Transplant-Related Disorder, Transplant-Related Disorder, Transplant-Related Disorder, Transplant-Related Disorder
Treatment Thoracic spine X-Ray
Clinical Study IdentifierNCT03811873
SponsorMayo Clinic
Last Modified on31 July 2021


Yes No Not Sure

Inclusion Criteria

First time liver transplant candidates deemed too early for liver transplant
hour urine Creatinine clearance of > 40 mg/dl. However bone turnover markers (beta CTx and P1NP) will be measured only in those with creatinine clearance >60mg/dl

Exclusion Criteria

Patients with prior solid organ transplantation
Liver/kidney combination will be excluded
Patients with 24 hr. urine creatinine clearance < 40mL/minute
Patients who have been on osteoporosis medications - Bisphosphonates [Fosamax (Alendronate), Actonel (Risedronate), Boniva (Ibandronate), or Reclast (Zoledronic acid)] Teriparatide (Forteo), Abaloparatide (Tymlos), Denosumab (Prolia), within the past 5 years
Use of other systemic medications that can effect bone remodeling including sex hormone replacement therapy (estrogen or testosterone), calcitonin, androgen deprivation therapy, aromatase inhibitors, or SERMS in the past 6 months
Underlying disease that significantly impacts bone metabolism such as primary hyperparathyroidism, hyperthyroidism, Paget's disease of bone, fibrous dysplasia, or malignancies with skeletal metastases
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note